| Calcifediol | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | |
| Calcifediol | hsa00340 | Histidine metabolism | 4.52E-02 | 1 | O95954 | FTCD | More | |
| Calcifediol | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.11E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
| Calcifediol | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Calcifediol | hsa00561 | Glycerolipid metabolism | 2.51E-02 | 2 | P51648, P23743 | ALDH3A2, DGKA | More | |
| Calcifediol | hsa00562 | Inositol phosphate metabolism | 7.30E-04 | 4 | P27987, Q96PE3, P19174, P42338 | ITPKB, INPP4A, PLCG1, PIK3CB | More | |
| Calcifediol | hsa00564 | Glycerophospholipid metabolism | 9.70E-03 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | |
| Calcifediol | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 8.72E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | |
| Calcifediol | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.46E-02 | 2 | P06865, Q9H4F1 | HEXA, ST6GALNAC4 | More | |
| Calcifediol | hsa00620 | Pyruvate metabolism | 2.51E-02 | 2 | P40925, P51648 | MDH1, ALDH3A2 | More | |
| Calcifediol | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.78E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Calcifediol | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | |
| Calcifediol | hsa01100 | Metabolic pathways | 3.67E-03 | 19 | Q9Y259, P15104, P51648, P42338, Q96PE3, P19174, P27987, Q13370, Q13956, P40925, P23743, P49619, O95954, Q02318, P43034, P09917, Q9UBX8, Q53FZ2, P35573 | CHKB, GLUL, ALDH3A2, PIK3CB, INPP4A, PLCG1, ITPKB, PDE3B, PDE6H, MDH1, DGKA, DGKG, FTCD, CYP27A1, PAFAH1B1, ALOX5, B4GALT6, ACSM3, AGL | More | |
| Calcifediol | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | |
| Calcifediol | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.46E-04 | 5 | Q92529, P19174, P42338, P08069, Q9NRA1 | SHC3, PLCG1, PIK3CB, IGF1R, PDGFC | More | |
| Calcifediol | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | |
| Calcifediol | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | |
| Calcifediol | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | |
| Calcifediol | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | |
| Calcifediol | hsa03320 | PPAR signaling pathway | 2.42E-03 | 4 | Q6PCB7, Q9UNU6, Q13133, Q02318 | SLC27A1, CYP8B1, NR1H3, CYP27A1 | More | |
| Calcifediol | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04012 | ErbB signaling pathway | 8.14E-04 | 5 | P16333, Q92529, P19174, P42338, P01106 | NCK1, SHC3, PLCG1, PIK3CB, MYC | More | |
| Calcifediol | hsa04014 | Ras signaling pathway | 6.46E-05 | 8 | P42338, Q92529, Q9NRA1, P49767, P08069, P63218, P50151, P19174 | PIK3CB, SHC3, PDGFC, VEGFC, IGF1R, GNG5, GNG10, PLCG1 | More | |
| Calcifediol | hsa04015 | Rap1 signaling pathway | 8.98E-03 | 5 | Q9NRA1, P49767, P08069, P42338, P19174 | PDGFC, VEGFC, IGF1R, PIK3CB, PLCG1 | More | |
| Calcifediol | hsa04020 | Calcium signaling pathway | 2.16E-02 | 4 | P27987, P19174, Q9NRA1, P49767 | ITPKB, PLCG1, PDGFC, VEGFC | More | |
| Calcifediol | hsa04062 | Chemokine signaling pathway | 4.35E-03 | 6 | P07948, P42338, P19174, Q92529, P63218, P50151 | LYN, PIK3CB, PLCG1, SHC3, GNG5, GNG10 | More | |
| Calcifediol | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04070 | Phosphatidylinositol signaling system | 3.67E-05 | 6 | P19174, P42338, P23743, P49619, Q96PE3, P27987 | PLCG1, PIK3CB, DGKA, DGKG, INPP4A, ITPKB | More | |
| Calcifediol | hsa04072 | Phospholipase D signaling pathway | 1.85E-04 | 6 | P42338, Q92529, P19174, Q14344, P23743, Q9NRA1 | PIK3CB, SHC3, PLCG1, GNA13, DGKA, PDGFC | More | |
| Calcifediol | hsa04110 | Cell cycle | 1.65E-04 | 8 | Q9UBD5, P06493, O75293, P30304, P33981, P42773, P01106, Q13547 | ORC3, CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC, HDAC1 | More | |
| Calcifediol | hsa04114 | Oocyte meiosis | 1.45E-04 | 6 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0, P08069 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | |
| Calcifediol | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | |
| Calcifediol | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | |
| Calcifediol | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04151 | PI3K-Akt signaling pathway | 2.55E-03 | 8 | P42338, Q9NRA1, P49767, P08238, P63218, P50151, O15335, P14784 | PIK3CB, PDGFC, VEGFC, HSP90AB1, GNG5, GNG10, CHAD, IL2RB | More | |
| Calcifediol | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04213 | Longevity regulating pathway - multiple species | 1.66E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Calcifediol | hsa04370 | VEGF signaling pathway | 2.44E-06 | 5 | P19174, P16298, P42338, Q05397, Q02750 | PLCG1, PPP3CB, PIK3CB, PTK2, MAP2K1 | More | |
| Calcifediol | hsa04371 | Apelin signaling pathway | 1.24E-02 | 4 | P63218, P50151, Q13370, Q14344 | GNG5, GNG10, PDE3B, GNA13 | More | |
| Calcifediol | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Calcifediol | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | |
| Calcifediol | hsa04510 | Focal adhesion | 3.52E-03 | 6 | P42338, O15335, P08069, Q9NRA1, P49767, Q92529 | PIK3CB, CHAD, IGF1R, PDGFC, VEGFC, SHC3 | More | |
| Calcifediol | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, Q02750, P08069, Q86SE9 | BMPR2, MAP2K1, IGF1R, PCGF5 | More | |
| Calcifediol | hsa04611 | Platelet activation | 4.11E-02 | 3 | P42338, Q14344, P07948 | PIK3CB, GNA13, LYN | More | |
| Calcifediol | hsa04613 | Neutrophil extracellular trap formation | 1.56E-02 | 5 | P19174, P11215, Q13547, P62807, Q16778 | PLCG1, ITGAM, HDAC1, HIST1H2BC, HIST2H2BE | More | |
| Calcifediol | hsa04630 | JAK-STAT signaling pathway | 3.20E-02 | 4 | P01106, P42224, P14784, Q13651 | MYC, STAT1, IL2RB, IL10RA | More | |
| Calcifediol | hsa04650 | Natural killer cell mediated cytotoxicity | 3.73E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Calcifediol | hsa04658 | Th1 and Th2 cell differentiation | 4.17E-09 | 7 | P07766, P19174, P01730, P06239, P42224, P14784, Q13761 | CD3E, PLCG1, CD4, LCK, STAT1, IL2RB, RUNX3 | More | |
| Calcifediol | hsa04659 | Th17 cell differentiation | 4.89E-07 | 10 | P25963, P19174, P01730, P06239, P42224, P14784, P84022, Q13485, P08238, P07766 | NFKBIA, PLCG1, CD4, LCK, STAT1, IL2RB, SMAD3, SMAD4, HSP90AB1, CD3E | More | |
| Calcifediol | hsa04660 | T cell receptor signaling pathway | 4.08E-02 | 5 | P19174, P16333, P07766, P01730, P06239 | PLCG1, NCK1, CD3E, CD4, LCK | More | |
| Calcifediol | hsa04662 | B cell receptor signaling pathway | 2.78E-02 | 3 | P42338, P07948, Q8N149 | PIK3CB, LYN, LILRA2 | More | |
| Calcifediol | hsa04664 | Fc epsilon RI signaling pathway | 7.30E-04 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | |
| Calcifediol | hsa04666 | Fc gamma R-mediated phagocytosis | 1.73E-02 | 3 | P07948, P42338, P19174 | LYN, PIK3CB, PLCG1 | More | |
| Calcifediol | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Calcifediol | hsa04722 | Neurotrophin signaling pathway | 4.87E-02 | 3 | P42338, P19174, Q92529 | PIK3CB, PLCG1, SHC3 | More | |
| Calcifediol | hsa04724 | Glutamatergic synapse | 1.73E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
| Calcifediol | hsa04725 | Cholinergic synapse | 1.73E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | |
| Calcifediol | hsa04726 | Serotonergic synapse | 3.41E-02 | 3 | P63218, P50151, P09917 | GNG5, GNG10, ALOX5 | More | |
| Calcifediol | hsa04727 | GABAergic synapse | 6.57E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
| Calcifediol | hsa04730 | Long-term depression | 3.83E-03 | 3 | Q14344, P08069, P07948 | GNA13, IGF1R, LYN | More | |
| Calcifediol | hsa04910 | Insulin signaling pathway | 4.11E-02 | 3 | Q92529, Q13370, P42338 | SHC3, PDE3B, PIK3CB | More | |
| Calcifediol | hsa04913 | Ovarian steroidogenesis | 1.16E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa04914 | Progesterone-mediated oocyte maturation | 1.40E-05 | 8 | P08069, Q17RY0, P42338, Q13370, Q9Y6D9, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, MAD1L1, HSP90AB1, RPS6KA3, MAP2K1 | More | |
| Calcifediol | hsa04915 | Estrogen signaling pathway | 4.76E-03 | 4 | P42338, Q92529, P08238, P11142 | PIK3CB, SHC3, HSP90AB1, HSPA8 | More | |
| Calcifediol | hsa04919 | Thyroid hormone signaling pathway | 1.64E-02 | 4 | P19174, P42224, Q13547, P01106 | PLCG1, STAT1, HDAC1, MYC | More | |
| Calcifediol | hsa04923 | Regulation of lipolysis in adipocytes | 3.64E-02 | 2 | Q13370, P42338 | PDE3B, PIK3CB | More | |
| Calcifediol | hsa04926 | Relaxin signaling pathway | 1.31E-03 | 5 | P42338, P63218, P50151, P49767, Q92529 | PIK3CB, GNG5, GNG10, VEGFC, SHC3 | More | |
| Calcifediol | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.47E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | |
| Calcifediol | hsa04935 | Growth hormone synthesis, secretion and action | 2.78E-02 | 3 | P19174, P42338, Q92529 | PLCG1, PIK3CB, SHC3 | More | |
| Calcifediol | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | |
| Calcifediol | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Calcifediol | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.95E-02 | 2 | Q06055, O15020 | ATP5G2, SPTBN2 | More | |
| Calcifediol | hsa05032 | Morphine addiction | 2.22E-02 | 3 | P63218, P50151, Q13370 | GNG5, GNG10, PDE3B | More | |
| Calcifediol | hsa05034 | Alcoholism | 4.79E-02 | 3 | Q13547, P62807, Q16778 | HDAC1, HIST1H2BC, HIST2H2BE | More | |
| Calcifediol | hsa05100 | Bacterial invasion of epithelial cells | 1.94E-03 | 5 | Q14141, Q05397, P42338, Q92529, Q96JJ3 | SEPT6, PTK2, PIK3CB, SHC3, ELMO2 | More | |
| Calcifediol | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
| Calcifediol | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
| Calcifediol | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Calcifediol | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Calcifediol | hsa05162 | Measles | 3.91E-02 | 4 | P14784, P07766, P42338, P11142 | IL2RB, CD3E, PIK3CB, HSPA8 | More | |
| Calcifediol | hsa05163 | Human cytomegalovirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, Q14344, P30101 | PIK3CB, GNG5, GNG10, GNA13, PDIA3 | More | |
| Calcifediol | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, P19174, P07948 | PIK3CB, GNG5, GNG10, PLCG1, LYN | More | |
| Calcifediol | hsa05169 | Epstein-Barr virus infection | 3.39E-03 | 8 | P01106, Q13547, P42338, P07948, P30101, Q13761, P42224, P07766 | MYC, HDAC1, PIK3CB, LYN, PDIA3, RUNX3, STAT1, CD3E | More | |
| Calcifediol | hsa05170 | Human immunodeficiency virus 1 infection | 7.03E-03 | 6 | P42338, P63218, P50151, P30101, P19174, P07766 | PIK3CB, GNG5, GNG10, PDIA3, PLCG1, CD3E | More | |
| Calcifediol | hsa05200 | Pathways in cancer | 3.05E-02 | 8 | P42338, P08238, P19174, P49767, P63218, P50151, Q14344, P14784 | PIK3CB, HSP90AB1, PLCG1, VEGFC, GNG5, GNG10, GNA13, IL2RB | More | |
| Calcifediol | hsa05202 | Transcriptional misregulation in cancer | 2.82E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa05203 | Viral carcinogenesis | 9.16E-03 | 5 | Q13547, P12814, P06493, P62807, Q16778 | HDAC1, ACTN1, CDK1, HIST1H2BC, HIST2H2BE | More | |
| Calcifediol | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Calcifediol | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Calcifediol | hsa05214 | Glioma | 8.47E-04 | 4 | P08069, Q92529, P42338, P19174 | IGF1R, SHC3, PIK3CB, PLCG1 | More | |
| Calcifediol | hsa05215 | Prostate cancer | 5.38E-03 | 4 | P08069, Q9NRA1, P08238, P42338 | IGF1R, PDGFC, HSP90AB1, PIK3CB | More | |
| Calcifediol | hsa05218 | Melanoma | 2.85E-03 | 3 | P08069, Q9NRA1, P42338 | IGF1R, PDGFC, PIK3CB | More | |
| Calcifediol | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Calcifediol | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Calcifediol | hsa05223 | Non-small cell lung cancer | 4.24E-02 | 3 | P19174, Q9HC35, O75293 | PLCG1, EML4, GADD45B | More | |
| Calcifediol | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
| Calcifediol | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Calcifediol | hsa05231 | Choline metabolism in cancer | 5.46E-07 | 6 | P42338, Q9NRA1, Q9Y259, P19174, P23743, P49619 | PIK3CB, PDGFC, CHKB, PLCG1, DGKA, DGKG | More | |
| Calcifediol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 7.21E-06 | 6 | P19174, P07766, P06239, P42224, Q9HC35, P01730 | PLCG1, CD3E, LCK, STAT1, EML4, CD4 | More | |
| Calcifediol | hsa05322 | Systemic lupus erythematosus | 2.75E-02 | 3 | P62807, Q16778, P12814 | HIST1H2BC, HIST2H2BE, ACTN1 | More | |
| Calcifediol | hsa05340 | Primary immunodeficiency | 4.24E-02 | 3 | P01730, P07766, P06239 | CD4, CD3E, LCK | More | |
